RU2013121799A - Набор для претаргетинга, способ и агенты, применяемые в нем - Google Patents
Набор для претаргетинга, способ и агенты, применяемые в нем Download PDFInfo
- Publication number
- RU2013121799A RU2013121799A RU2013121799/15A RU2013121799A RU2013121799A RU 2013121799 A RU2013121799 A RU 2013121799A RU 2013121799/15 A RU2013121799/15 A RU 2013121799/15A RU 2013121799 A RU2013121799 A RU 2013121799A RU 2013121799 A RU2013121799 A RU 2013121799A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- aryl
- group
- independently
- bio
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0495—Pretargeting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Radiology & Medical Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nanotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10187619.1 | 2010-10-14 | ||
| EP10187619 | 2010-10-14 | ||
| PCT/IB2011/054481 WO2012049624A1 (en) | 2010-10-14 | 2011-10-11 | Pretargeting kit, method and agents used therein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013121799A true RU2013121799A (ru) | 2014-11-20 |
Family
ID=43736149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013121799/15A RU2013121799A (ru) | 2010-10-14 | 2011-10-11 | Набор для претаргетинга, способ и агенты, применяемые в нем |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9463256B2 (enExample) |
| EP (1) | EP2627358B1 (enExample) |
| JP (2) | JP6063384B2 (enExample) |
| RU (1) | RU2013121799A (enExample) |
| WO (1) | WO2012049624A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9463256B2 (en) * | 2010-10-14 | 2016-10-11 | Koninklijke Philips N.V. | Pretargeting kit, method and agents used therein |
| EP2522369A1 (en) * | 2011-05-09 | 2012-11-14 | Koninklijke Philips Electronics N.V. | Pretargeting kit, method and agents used therein |
| DK2709667T3 (da) | 2011-05-16 | 2022-07-04 | Tagworks Pharmaceuticals B V | Bio-orthogonal lægemiddelaktivering |
| WO2013176845A1 (en) * | 2012-05-21 | 2013-11-28 | Agilent Technologies, Inc. | Retro diels alder reaction as a cleavable linker in dna/rna applications |
| FI2922574T3 (fi) * | 2012-11-22 | 2023-08-11 | Tagworks Pharmaceuticals B V | Kemiallisesti pilkkoutuva ryhmä |
| WO2014081300A1 (en) * | 2012-11-22 | 2014-05-30 | Tagworks Pharmaceuticals B.V. | Channel protein activatable liposomes |
| WO2014081299A1 (en) * | 2012-11-22 | 2014-05-30 | Tagworks Pharmaceuticals B.V. | Activatable liposomes |
| US20150297741A1 (en) * | 2012-11-22 | 2015-10-22 | Tagworks Pharmaceuticals B.V. | Bio-orthogonal drug activation |
| EP2948186A4 (en) * | 2013-01-25 | 2016-10-05 | Sloan Kettering Inst Cancer | TETRAZINE / TRANSCYCLOOKTENE IN SOLID PHASE SYNTHESIS MARKED PEPTIDE |
| US9366784B2 (en) | 2013-05-07 | 2016-06-14 | Corning Incorporated | Low-color scratch-resistant articles with a multilayer optical film |
| US9110230B2 (en) | 2013-05-07 | 2015-08-18 | Corning Incorporated | Scratch-resistant articles with retained optical properties |
| CN105611914B (zh) | 2013-06-19 | 2020-09-08 | 加利福尼亚大学董事会 | 局部递送治疗剂的化学构造物 |
| DK3089690T3 (en) | 2014-01-04 | 2018-12-03 | Craniovation Inc | APPARATUS FOR USING PHOTODYNAMIC THERAPY |
| CA2939265A1 (en) * | 2014-02-10 | 2015-08-13 | Mcmaster University | Targeted molecular imaging contrast agents |
| AU2015229014B2 (en) | 2014-03-14 | 2019-07-25 | The Regents Of The University Of California | TCO conjugates and methods for delivery of therapeutic agents |
| WO2015154082A1 (en) * | 2014-04-04 | 2015-10-08 | President And Fellows Of Harvard College | Refillable drug delivery devices and methods of use thereof |
| US11267973B2 (en) | 2014-05-12 | 2022-03-08 | Corning Incorporated | Durable anti-reflective articles |
| US9790593B2 (en) | 2014-08-01 | 2017-10-17 | Corning Incorporated | Scratch-resistant materials and articles including the same |
| WO2016025480A1 (en) | 2014-08-11 | 2016-02-18 | The General Hospital Corporation | Cyclooctenes for bioorthogonol reactions |
| CN117567535A (zh) | 2015-09-10 | 2024-02-20 | 坦伯公司 | 生物正交组合物 |
| CN112213802A (zh) | 2015-09-14 | 2021-01-12 | 康宁股份有限公司 | 减反射制品以及包含其的显示器装置 |
| ES2874930T3 (es) * | 2015-10-08 | 2021-11-05 | Harvard College | Dispositivos recargables de administración de fármacos y procedimientos de uso de los mismos |
| WO2018004338A1 (en) | 2016-06-27 | 2018-01-04 | Tagworks Pharmaceuticals B.V. | Cleavable tetrazine used in bio-orthogonal drug activation |
| WO2018187740A1 (en) | 2017-04-07 | 2018-10-11 | Shasqi, Inc. | Bioorthogonal compositions |
| US11560384B2 (en) | 2017-05-04 | 2023-01-24 | University Of Utah Research Foundation | Benzonorbornadiene derivatives and reactions thereof |
| BR112019023249A8 (pt) * | 2017-05-05 | 2021-02-23 | Centre For Probe Dev And Commercialization | anticorpos monoclonais igf-1r e usos dos mesmos |
| EP3651741A4 (en) | 2017-07-14 | 2021-04-21 | The Penn State Research Foundation | Compositions and methods for targeted delivery of therapeutic and/or diagnostic species |
| GB201720769D0 (en) | 2017-12-13 | 2018-01-24 | Univ Of Northumbria At Newcastle | Pericyclic reactions |
| EA202091420A1 (ru) | 2017-12-18 | 2020-09-10 | Янссен Байотек, Инк. | Радиоактивное мечение полипептидов |
| ES2975330T3 (es) | 2018-05-04 | 2024-07-04 | Tagworks Pharmaceuticals B V | Compuestos que comprenden un enlazador para aumentar la estabilidad del trans-cicloocteno |
| EP3787691A1 (en) | 2018-05-04 | 2021-03-10 | Tagworks Pharmaceuticals B.V. | Tetrazines for high click conjugation yield in vivo and high click release yield |
| KR102824070B1 (ko) | 2018-08-17 | 2025-06-23 | 코닝 인코포레이티드 | 얇고, 내구성 있는 반사-방지 구조를 갖는 무기산화물 물품 |
| US20200115389A1 (en) | 2018-09-18 | 2020-04-16 | Nikang Therapeutics, Inc. | Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors |
| KR20210142105A (ko) | 2019-02-13 | 2021-11-24 | 알페이오스 메디컬, 인코포레이티드 | 비침습적 초음파역학 요법 |
| AU2020282737A1 (en) | 2019-05-29 | 2021-12-16 | Sonalasense, Inc. | Sonosensitization |
| IL289095A (en) | 2019-06-17 | 2022-02-01 | Tagworks Pharmaceuticals B V | Activating components to cleave labels from biomolecules in vivo |
| US12386101B2 (en) | 2020-07-09 | 2025-08-12 | Corning Incorporated | Textured region of a substrate to reduce specular reflectance incorporating surface features with an elliptical perimeter or segments thereof, and method of making the same |
| WO2022032283A2 (en) | 2020-08-07 | 2022-02-10 | Alpheus Medical, Inc. | Ultrasound arrays for enhanced sonodynamic therapy for treating cancer |
| EP4108669A1 (en) * | 2021-06-24 | 2022-12-28 | Institute Of Organic Chemistry And Biochemistry As CR, V.V.I. | Carbohydrate derivatives and kits for cell surface labeling |
| WO2025059685A1 (en) * | 2023-09-15 | 2025-03-20 | Tambo, Inc. | Methods for in vivo targeted delivery of a payload |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| US5326856A (en) | 1992-04-09 | 1994-07-05 | Cytogen Corporation | Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding |
| JP2009512641A (ja) * | 2005-10-04 | 2009-03-26 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | ［３＋２］アジド−アルキン環付加を使用するターゲットにされたイメージング及び／又は治療 |
| CN102271712B (zh) * | 2008-10-31 | 2015-11-25 | 通用医疗公司 | 用于将物质递送至生物靶标的组合物和方法 |
| EP2419142B1 (en) | 2009-04-16 | 2020-01-15 | Tagworks Pharmaceuticals B.V. | Pretargeting kit, method and agents used therein |
| US9463256B2 (en) * | 2010-10-14 | 2016-10-11 | Koninklijke Philips N.V. | Pretargeting kit, method and agents used therein |
| FI2922574T3 (fi) * | 2012-11-22 | 2023-08-11 | Tagworks Pharmaceuticals B V | Kemiallisesti pilkkoutuva ryhmä |
-
2011
- 2011-10-11 US US13/877,725 patent/US9463256B2/en active Active
- 2011-10-11 JP JP2013533311A patent/JP6063384B2/ja active Active
- 2011-10-11 EP EP11776566.9A patent/EP2627358B1/en active Active
- 2011-10-11 WO PCT/IB2011/054481 patent/WO2012049624A1/en not_active Ceased
- 2011-10-11 RU RU2013121799/15A patent/RU2013121799A/ru unknown
-
2016
- 2016-07-12 JP JP2016137224A patent/JP6368745B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014506869A (ja) | 2014-03-20 |
| US20130189184A1 (en) | 2013-07-25 |
| EP2627358A1 (en) | 2013-08-21 |
| EP2627358C0 (en) | 2024-03-27 |
| EP2627358B1 (en) | 2024-03-27 |
| JP6063384B2 (ja) | 2017-01-18 |
| WO2012049624A1 (en) | 2012-04-19 |
| CN103269721A (zh) | 2013-08-28 |
| JP6368745B2 (ja) | 2018-08-01 |
| US9463256B2 (en) | 2016-10-11 |
| JP2016193934A (ja) | 2016-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013121799A (ru) | Набор для претаргетинга, способ и агенты, применяемые в нем | |
| JP2016193934A5 (enExample) | ||
| RU2013133813A (ru) | Средства для выведения биомолекул из кровотока | |
| RU2011146322A (ru) | Набор для предварительного придания направленности действия, способ и средства, применяемые в нем | |
| KR101931382B1 (ko) | 토륨 방사성 핵종 및 히드록시피리디논 함유 리간드를 포함하는 표적화된 알파-입자 방출 복합체 | |
| EP2357166B1 (en) | Auto magnetic metal salen complex compound | |
| PT92619B (pt) | Processo para a preparacao de complexos do acido aminofosfonico e de formulacoes com base no referido acido | |
| US20050238578A1 (en) | High dose radionuclide complexes for bone marrow suppression | |
| CA3171183A1 (en) | Fap-targeted radiopharmaceuticals and imaging agents, and uses related thereto | |
| NO20051108L (no) | Cytotoksiske midler som inneholder nye virksomme taksaner og terapeutisk anvendelse av disse | |
| RU2011107752A (ru) | Агенты, связывающиеся с psma, и их применение | |
| JP6321673B2 (ja) | 放射線と組み合わせて使用するための放射線増感剤化合物 | |
| JP2001517705A (ja) | 細胞傷害性剤の効力を増強するためのビタミンｄ誘導体の使用 | |
| KR20080039508A (ko) | 인데노이소퀴놀리논 유사체 및 이의 사용 방법 | |
| AR068897A1 (es) | Inhibidores de proteasoma | |
| WO2008043911A3 (fr) | Complexes chelates dendritiques, leurs procedes de fabrication et compositions pharmaceutiques les contenant | |
| US6670456B2 (en) | Actinium-225 complexes and conjugates for targeted radiotherapy | |
| Houston et al. | The systemic treatment of bone metastases | |
| SG145570A1 (en) | 4-æ7-halo-2-quino(xa-)linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents | |
| CA2103556C (en) | Bicyclopolyazamacrocyclophosphonic acids, their complexes and conjugates, for use as contrast agents, and processes for their preparation | |
| RU2014132184A (ru) | Калмангафодипир, новое химическое соединение и другие смешанные комплексные соединения с металлами, способы получения, композиции и способы лечения | |
| El-Mabhouh et al. | Preclinical investigations of drug and radionuclide conjugates of bisphosphonates for the treatment of metastatic bone cancer | |
| KR101678865B1 (ko) | 암의 치료에 사용하기 위한 화합물들 | |
| US20040126317A1 (en) | Skeletal-targeted radiation to treat bone-associated pathologies | |
| Bruntsch et al. | Phase-I study of mafosfamide-cyclohexylamine (ASTA-Z-7557, NSC 345 842) and limited phase-I data on mafosfamide-lysine |